Theravance Biopharma Inc. (NASDAQ:TBPH)’s share price shot up 2.8% during trading on Monday . The stock traded as high as $28.98 and last traded at $28.98, with a volume of 86,814 shares traded. The stock had previously closed at $28.18.

Several brokerages have recently commented on TBPH. Leerink Swann reaffirmed a “buy” rating on shares of Theravance Biopharma in a research report on Saturday, June 4th. Bank of America Corp. cut shares of Theravance Biopharma from a “buy” rating to a “neutral” rating in a research report on Thursday, May 5th. Evercore ISI began coverage on shares of Theravance Biopharma in a research report on Monday. They set a “buy” rating and a $41.00 price target on the stock. Guggenheim began coverage on shares of Theravance Biopharma in a research report on Monday, June 20th. They set a “buy” rating and a $30.00 price target on the stock. Finally, Zacks Investment Research raised shares of Theravance Biopharma from a “hold” rating to a “buy” rating and set a $26.00 price target on the stock in a research report on Tuesday, July 12th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. Theravance Biopharma currently has a consensus rating of “Hold” and an average price target of $32.00.

The firm’s market cap is $1.35 billion. The stock has a 50-day moving average price of $25.58 and a 200 day moving average price of $21.63.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.05) by $0.01. Equities analysts expect that Theravance Biopharma Inc. will post ($4.03) EPS for the current fiscal year.

In related news, EVP Bradford J. Shafer sold 49,122 shares of Theravance Biopharma stock in a transaction on Monday, August 22nd. The shares were sold at an average price of $27.46, for a total value of $1,348,890.12. Following the transaction, the executive vice president now owns 241,686 shares in the company, valued at approximately $6,636,697.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Brett K. Haumann sold 4,491 shares of Theravance Biopharma stock in a transaction on Thursday, August 25th. The stock was sold at an average price of $27.99, for a total transaction of $125,703.09. Following the completion of the transaction, the senior vice president now owns 188,293 shares in the company, valued at approximately $5,270,321.07. The disclosure for this sale can be found here.

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.